OpenNano,
Journal Year:
2022,
Volume and Issue:
7, P. 100041 - 100041
Published: April 6, 2022
Cancer,
the
second
major
cause
of
death
after
cardiovascular
disease
has
been
reported
to
have
resulted
in
over
10
million
deaths
worldwide
per
year,
on
average.
Resistance
therapeutic
interventions
is
a
definitive
characteristic
cancer,
where
acquired
resistance
become
challenge
that
significantly
reduced
anti-tumor
efficiency
cancer
therapy.
The
tumor
microenvironment
(TME)
heavily
responsible
for
these
cell-targeted
drug
delivery
system
challenges
due
its
abundant
physiological
and
pathological
barriers
impair
tumoral
penetration
distribution
nanotherapeutics.
However,
unique
TME
characteristics
also
make
an
attractive
target
focus
intense
research
development
antitumor
nanomedicine
strategies
can
directly
or
modulate
it.
In
this
review,
we
summarize
developed
overcome
obstacles
against
nano-drug
consequently
improve
efficiency.
Advanced Science,
Journal Year:
2023,
Volume and Issue:
10(31)
Published: Sept. 22, 2023
Abstract
In
situ
vaccination
is
a
desirable
strategy
for
cancer
immunotherapy
due
to
its
convenience
and
capacity
target
tumor
antigens.
Here,
an
in
nanovaccine
based
on
cationic
peptide
with
cholesterol‐modified,
DP7‐C,
rationally
designed,
developed
that
easy
preparate.
The
includes
cocktail
small
interfering
RNAs
(siRNAs)
immunologic
adjuvant
CpG
ODNs,
has
synergistic
effect
the
treatment.
This
can
induce
cell
death,
promote
antigen
presentation
relieve
immune
suppression
microenvironment
(TME).
Moreover,
this
administered
CT26
(hot)
B16F10
(cold)
model
mice,
which
it
targeted
primary
tumors
induced
systemic
antitumor
immunity
inhibit
metastasis.
It
validated
convert
cold
into
hot
tumors.
Furthermore,
increased
response
anti‐PD‐1
therapy
by
modulating
TME
both
CT26‐
B16F10‐tumor‐bearing
mice.
siRNA
cocktail/CpG
ODN/self‐assembling
simple
universal
tool
effectively
generate
specific
antigens
be
combined
immuno‐oncology
agents
enhance
activity.
versatile
methodology
provides
alternative
approach
developing
nanovaccines.
Frontiers in Pharmacology,
Journal Year:
2022,
Volume and Issue:
13
Published: March 18, 2022
Autoimmune
diseases
and
malignant
tumors
are
the
two
hotspots
difficulties
that
currently
being
studied
concerned
by
medical
field.
The
use
of
PD-1/PD-L1
inhibitors
improves
prognosis
advanced
tumors,
but
excessive
immune
responses
can
also
induce
immune-related
adverse
events
(irAEs).
Due
to
this
concern,
many
clinical
trials
exclude
cancer
patients
with
preexisting
autoimmune
disease
(AID).
This
review
outlines
possible
mechanisms
irAE,
discusses
safety
efficacy
in
AID,
emphasizes
importance
early
recognition,
continuous
monitoring,
multidisciplinary
cooperation
prevention
management
AID.
Biomaterials Research,
Journal Year:
2023,
Volume and Issue:
27(1)
Published: Feb. 9, 2023
The
emergence
of
cancer
immunotherapies,
notably
immune
checkpoint
inhibitors,
has
revolutionized
anti-cancer
treatments.
These
treatments,
however,
have
been
reported
to
be
effective
in
a
limited
range
cancers
and
cause
immune-related
adverse
effects.
Thus,
for
broader
applicability
enhanced
responsiveness
solid
tumor
immunotherapy,
immunomodulation
the
microenvironment
is
crucial.
Transforming
growth
factor-β
(TGF-β)
implicated
reducing
immunotherapy
by
promoting
M2-type
differentiation
macrophages
facilitating
cell
metastasis.
In
this
study,
we
developed
macrophage
membrane-coated
nanoparticles
loaded
with
TGF-βR1
kinase
inhibitor,
SD-208
(M[Formula:
see
text]-SDNP).
Inhibitions
M2
polarization
epithelial-to-mesenchymal
transition
(EMT)
cells
were
comprehensively
evaluated
through
vitro
vivo
experiments.
Bio-distribution
study
therapeutic
effects
M[Formula:
text]-SDNP
investigated
orthotopic
breast
model
intraveneously
injected
metastasis
model.
text]-SDNPs
effectively
inhibited
converted
immunosuppressive
(cold
tumor)
into
an
immunostimulatory
(hot
tumor),
specific
targeting
blockade
differentiation.
Administration
considerably
augmented
population
cytotoxic
T
lymphocytes
(CTLs)
tissue,
thereby
significantly
enhancing
which
demonstrates
robust
effect
conjunction
anti-PD-1
antibodies.
Collectively,
inhibitors
was
demonstrated
combination
treatment
antibody.
This
suggests
promising
direction
future
strategies,
utilizing
bio-inspired
nanotechnology
improve
efficacy
immunotherapy.
Materials Today Advances,
Journal Year:
2021,
Volume and Issue:
13, P. 100203 - 100203
Published: Dec. 31, 2021
With
the
focus
in
field
of
cancer
nanomedicine
shifting
from
direct
tumor
targeting
to
modulation
immune
system,
new
opportunities
arise
for
employment
nanocarrier
systems.
Polymeric
nanovesicles,
or
polymersomes,
have
been
under
investigation
as
a
potential
platform
past
decades.
These
investigations
enhanced
our
fundamental
knowledge
on
how
tailor
physicochemical
properties,
such
size
and
shape,
surface
chemistry
functionalization,
membrane
characteristics.
The
versatile
nature
high
structural
stability
polymersomes
makes
them
suitable
treatment
that
goes
beyond
drug
delivery.
Rational
design
allows
spatiotemporal
control
over
function
specific
cell
targets
enhance
immunotherapy.
This
review
provides
perspective
view
multifunctional
vivo
We
discuss
implement
field,
elaborate
their
considerations
immunotherapeutic
applications
compare
with
lipid
nanoparticles
other
relevant
Current
challenges
future
perspectives
are
addressed
underline
what
is
needed
employ
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(7), P. 1821 - 1821
Published: June 26, 2023
Cancer
immunotherapy
can
significantly
prevent
tumor
growth
and
metastasis
by
activating
the
autoimmune
system
without
destroying
normal
cells.
Although
cancer
has
made
some
achievements
in
clinical
treatment,
it
is
still
restricted
systemic
immunotoxicity,
immune
cell
dysfunction,
heterogeneity,
immunosuppressive
microenvironment
(ITME).
Biomimetic
cell-derived
nanoparticles
are
attracting
considerable
interest
due
to
their
better
biocompatibility
lower
immunogenicity.
Moreover,
biomimetic
achieve
different
preferred
biological
effects
inherent
abundant
source
cell-relevant
functions.
This
review
summarizes
latest
developments
for
immunotherapy,
discusses
applications
of
each
analyzes
challenges
transformation.
Journal of Pharmacy And Bioallied Sciences,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 28, 2025
A
BSTRACT
Introduction:
Immunotherapy
has
revolutionized
the
treatment
of
metastatic
melanoma,
offering
prolonged
survival
and
improved
outcomes.
Checkpoint
inhibitors
like
PD-1/PD-L1
have
demonstrated
significant
efficacy
in
modulating
immune
system’s
response
to
tumors.
This
randomized
controlled
trial
aims
evaluate
these
therapies
compared
standard
care.
Methods:
was
conducted
on
patients
with
advanced
who
were
assigned
either
immunotherapy
or
traditional
chemotherapy.
Parameters
included
progression-free
(PFS),
overall
(OS),
immune-related
adverse
events.
Data
analysis
using
appropriate
statistical
tests,
P
values
set
at
<
0.05
for
significance.
Results:
significantly
PFS
OS
chemotherapy
(
0.01).
Adverse
events
manageable
consistent
known
profiles
checkpoint
inhibitors.
Conclusion:
provides
a
superior
therapeutic
option
outcomes
toxicity.
Further
research
is
needed
refine
patient
selection
optimize
combinations.
Discover Oncology,
Journal Year:
2025,
Volume and Issue:
16(1)
Published: March 11, 2025
Abstract
Background
Lung
cancer
is
one
of
the
most
common
malignant
tumors
worldwide.
This
article
aims
to
review
current
research
status
and
trends
in
PD-1/PD-L1
inhibitor
immunotherapy.
Method
On
basis
Web
Science
Core
Collection
database,
literature
on
immunotherapy
lung
patients
was
searched
analyzed
for
all
years
up
August
5,
2023.
Bibliometric
techniques
were
employed,
including
CiteSpace
(6.1.R6),
VOSviewer,
Bibliometrix
package
R,
examine
publication
counts,
countries,
institutions,
authors,
journals,
cited
literature,
keywords,
trends.
Results
A
total
1,252
documents
included
following
screening
process.
The
analysis
revealed
that
China
had
highest
number
publications
(512),
whereas
institution
with
UDICE
French
Association
Research
Universities
Union
(193).
journal
articles
Journal
Immunotherapy
Cancer
(48),
prolific
author
Zhou
Caixun
from
Tongji
University
(20).
Co-citation
Borghaei
H’s
2015
New
England
Medicine
citation
frequency.
clustering
results
indicated
frequently
referenced
keywords
predictors,
treatment
monitoring,
hyperprogressive
diseases.
There
a
growing
trend
toward
combination
therapies,
such
as
dual
immune
checkpoint
inhibitors,
into
molecular
mechanisms
within
tumor
microenvironment,
aimed
at
enhancing
efficacy
reducing
adverse
effects.
Conclusion
indicates
inhibitors
are
pivotal
this
domain
focuses
identifying
biomarkers
addressing
evasion
resistance
maximize
efficacy,
mitigating
Cells,
Journal Year:
2025,
Volume and Issue:
14(8), P. 587 - 587
Published: April 12, 2025
Lung
cancer
with
the
highest
number
of
new
cases
diagnosed
in
Europe
and
Poland,
remains
an
example
malignancy
a
very
poor
prognosis
despite
recent
progress
medicine.
Different
treatment
strategies
are
now
available
for
therapy
based
on
its
type,
molecular
subtype
other
factors
including
overall
health,
stage
disease
profile.
Immunotherapy
is
emerging
as
potential
addition
to
surgery,
chemotherapy,
radiotherapy
or
targeted
therapies,
but
also
considered
mainstay
mode.
This
combination
area
active
investigation
order
enhance
efficacy
overcome
resistance.
Due
complexity
dynamic
cancer’s
ecosystem,
novel
therapeutic
targets
need
continued
research
into
cellular
mechanisms
within
tumour
microenvironment.
From
genetic
point
view,
several
signatures
ranging
from
few
mutated
genes
hundreds
them
have
been
identified
associated
resistance
metastatic
potential.
ML
techniques
AI
can
predictive
model
prognosis.
Here,
we
present
overview
already
existing
approaches,
current
findings
key
aspects
immunotherapy,
such
immune
checkpoint
inhibitors
(ICIs),
biomarkers
like
PD-L1
expression,
mutation
burden,
immunoscore,
neoantigens,
well
their
roles
markers
response
